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(CBD)-Containing Treats Did Not
Affect Canine Daily Voluntary Activity
Elizabeth M. Morris 1, Susanna E. Kitts-Morgan 2, Dawn M. Spangler 2, Jessica Gebert 2,
Eric S. Vanzant 1, Kyle R. McLeod 1 and David L. Harmon 1*
1Department of Animal and Food Sciences, University of Kentucky, Lexington, KY, United States, 2College of Veterinary
Medicine, Lincoln Memorial University, Harrogate, TN, United States
Growing public interest in the use of cannabidiol (CBD) for companion animals has
amplified the need to elucidate potential impacts. The purpose of this investigation
was to determine the influence of CBD on the daily activity of adult dogs. Twenty-four
dogs (18.0 ± 3.4 kg, 9 months−4 years old) of various mixed breeds were utilized in a
randomized complete block design with treatments targeted at 0 and 2.5mg (LOW)
and at 5.0mg (HIGH) CBD/kg body weight (BW) per day split between two treats
administered after twice-daily exercise (0700–0900 and 1,700–1,900 h). Four hours each
day [1,000–1,200 h (a.m.) and 1,330–1,530 h (p.m.)] were designated as times when
no people entered the kennels, with 2 h designated as Quiet time and the other 2 h as
Music time, when calming music played over speakers. Quiet and Music sessions were
randomly allotted to daily a.m. or p.m. times. Activity monitors were fitted to dogs’ collars
for continuous collection of activity data. Data were collected over a 14-day baseline
period to establish the activity patterns and block dogs by activity level (high or low) before
randomly assigning dogs within each block to treatments. After 7 days of treatment
acclimation, activity data were collected for 14 days. Data were examined for differences
using the MIXED procedure in SAS including effects of treatment, day, session (Quiet or
Music), time of day (a.m. or p.m.), and accompanying interactions. CBD (LOW and HIGH)
did not alter the total daily activity points (P= 0.985) or activity duration (P= 0.882). CBD
tended (P= 0.071) to reduce total daily scratching compared with the control. Dogs were
more active in p.m. sessions than in a.m. sessions (P < 0.001). During the p.m. session,
dogs receiving HIGH tended (P = 0.091) to be less active than the control (CON). During
the a.m. and p.m. sessions, CBD reduced scratching compared with CON (P = 0.030).
CBD did not affect the activity duration during exercise periods (P= 0.143). These results
indicate that, when supplemented with up to 4.5mg CBD/kg BW/day, CBD does not
impact the daily activity of adult dogs, but may exert an antipruritic effect.
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INTRODUCTION
Pet owners and caretakers are increasingly interested in
monitoring their animals’ behavior and activity as indicators of
health and well-being. While several subjective measures like the
Canine Brief Pain Inventory and the Hudson Visual Analog Scale
are available for use (1, 2), the ability to measure activity through
objective, non-invasive means such as with accelerometers is a
potentially preferable tool that can provide an impartial measure
of animal activity (3–6). The use of accelerometers, kinesiology,
and gait analysis are becoming popular methods by which to
evaluate the health status of an animal as well as response to
treatment. Several triaxial accelerometers have been validated for
the measurement of canine activity and can be easily attached to
a collar or harness for home use (7–10). They have been used
to evaluate the effectiveness of treatments for osteoarthritis and
pruritic behaviors (11–14), the effects of exercise and rest on the
voluntary activity of active sled dogs (15, 16), and to predict rest
in dogs and sleep in humans (17–19).
Normal activity of healthy dogs is influenced by many factors,
including breed, age, degree of socialization, and amount of
exercise (20–22). Additionally, canine activity may be negatively
influenced by factors such as disease, chronic illnesses like
osteoarthritis, or behavioral issues such as anxiety (11, 23, 24).
There are also certain circumstances where canine activity needs
to be reduced as a result of normal activity in high-energy
dogs, pruritic behaviors like scratching, or anxious behaviors like
pacing and destruction. Activity may also need to be prevented
or reduced following an illness, medical treatment, or surgical
procedure (13, 24). In such instances, many turn to medications
like sedatives or antidepressants that have been shown to reduce
canine activity (25). However, some pet owners may be hesitant
to turn to such medications due to potential side effects, cost,
or personal bias against their use (26, 27). Instead, they often
investigate alternatives to conventional medications, such as
cannabidiol (CBD).
Cannabidiol is one of over 100 known cannabinoids produced
in the glandular trichomes of Cannabis sativa. There has been
considerable interest in the use of CBD for both humans and
companion animals due to its reported benefits, such as analgesia,
anti-inflammatory, anxiolytic, and sedative effects (28–30). The
analgesic effect of CBD has been documented in rodent and
human models (31–33), and the use of oral and transmucosal
CBD oil formulations increased the Canine Brief Pain Inventory
(CBPI) and Hudson scores in dogs with osteoarthritis, suggesting
an increase in activity and comfort with CBD use (34, 35).
However, despite evidence of an anxiolytic effect of CBD in both
rodents and humans with doses ranging from 2.5 to 10 mg/kg
(36–38), a recent report failed to demonstrate an anxiolytic effect
of treats containing 1.4mg CBD/kg body weight (BW) in dogs
exposed to a noise-induced fear response test (39). Other effects
attributed to CBD, such as sedative effects, are thought to be
biphasic. Larger doses have been shown to exert sedative effects
in both rats and humans, whereas low doses of CBDmay increase
wakefulness (40–42).While the effect of CBD on sedation has not
been specifically investigated in a canine model, a preliminary
investigation of the safety of escalating CBD doses in 20 healthy
dogs reported mild constitutional adverse events recorded for
dogs receiving 1.7–64.7 mg/kg CBD oil, which included both
lethargy and hyperesthesia (43). A similar investigation into the
safety of a 1:20 19-tetrahydrocannabinol (THC)/CBD herbal
extract reported mild neurological adverse events, like ataxia and
delayed hopping, after single and multiple oral doses of 2 and 5
mg/kg CBD extract (44). While adverse events in both studies
were mild and rare, they do highlight the potential of CBD to
cause undesirable side effects as well as the need for continuing
research evaluating the safety and efficacy of CBD use in dogs.
Despite the lack of scientific evidence demonstrating the
safety and efficacy of CBD use in dogs, a recent survey of over
1,000 dog owners recruited on social media showed that almost
80% of the owners surveyed had purchased hemp or marijuana
products for their dogs to provide pain relief, relieve anxiety,
aid with sleep, and treat other health conditions. Many also
indicated that they believed hemp products were more effective
than conventional medications (26, 27). The study population
included owners of both healthy and diseased animals as well
as owners that either had or had not ever purchased hemp
products for their dogs; however, this is likely an overestimation
of the overall hemp use in companion animals due to the surveys
being shared primarily within social media groups dedicated to
cannabis use in pets. Nevertheless, these surveys provide insight
into the overwhelmingly favorable perceptions of pet owners on
the safety and efficacy of CBD use in companion animals. Due
to this interest in the use of CBD in companion animals, there
is a critical need for further evaluation of CBD use in dogs
and its potential effects on canine activity. Thus, the objective
of the current study was to determine the impact of CBD on
the daily activity of healthy adult dogs with the underlying
hypothesis that CBD would reduce the overall daily activity of
dogs compared with the control. This hypothesis was tested using
triaxial accelerometers to measure the activity of dogs receiving
two levels of CBD administration compared to a control.
MATERIALS AND METHODS
This study was approved by the Lincoln Memorial University
(LMU) institutional animal care and use committee (protocol
1911-RES) before the start of the study. All housing and
husbandry were provided in accordance with the AnimalWelfare
Act, the Guide for the Care and Use of Laboratory Animals (8th
ed.), and all applicable LMU protocols.
Subjects and Housing
Thirty neutered adult dogs (15 males, 15 females, 9 months to
4 years old, 17.6 ± 3.4 kg) of various mixed breeds, including
terrier, hound, Bassett, shepherd, border collie, husky, cur, lab,
boxer, and pug mixes, were received at the LMU DeBusk
Veterinary Teaching Center (DVTC) from a local shelter for
inclusion in this study. The shelter was asked to provide dogs
weighing 16 ± 4 kg. Additionally, the shelter was informed and
gave consent for the use of the dogs for research purposes
before their arrival. Before beginning the experiment, each
dog had a complete blood count (CBC) and serum chemistry
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analysis (IDEXX Laboratories, Inc., Westbrook, ME) performed,
along with a physical evaluation by a veterinarian and a fecal
examination to rule out any underlying disease that might
preclude enrollment. Dogs were excluded if they demonstrated
serious behavioral issues, such as extreme fear or human
aggression that would endanger research personnel, were severely
emaciated or obese, classified as a body condition score <2 or
>4 on a five-point scale (where one is emaciated and five is
obese), or if the initial evaluations revealed an underlying disease
that required more than routine treatments, such as heartworm
infection, metabolic or infectious disease, and mobility issues.
Three dogs were excluded due to positive heartworm tests
and another three dogs excluded for behavioral concerns. The
remaining 24 dogs (12 males, 12 females, 9 months to 4 years old,
18.0 ± 3.4 kg) were selected for inclusion in the study. The dogs
were individually housed in 1.2 × 1.8-m cages within one of two
dog kennels at the LMU DVTC for the duration of the study.
Diets and Treatments
Dogs were fed Purina Pro Plan EN Gastroenteric Fiber Balance
Dry Dog Food (Nestle Purina Inc., St. Louis, MO) to meet
the daily metabolizable energy requirements of neutered adult
dogs at maintenance, calculated as (70 × BW0.75) × 1.6, and
split into two meals per day fed between 0700 and 0900 h and
between 1,700 and 1,900 h each day. Dogs were weighed and
body condition scored (five-point scale) weekly and the diets
adjusted accordingly. Treatments were arranged in a randomized
complete block design and consisted of 0 (placebo treats, CON),
34.0± 1.16 (LOW), or 75.6± 5.86 (HIGH) mg CBD/day. CBD is
a constituent of a proprietary industrial hemp extract (AgTech
Scientific, Paris, KY) that was incorporated into treats and
administered in the form of two treats daily, each containing half
the daily dose. Both control and CBD treats were composed of the
following ingredients: chicken, chicken liver, Asian carp, catfish,
and—in the case of CBD treats—industrial hemp extract. While
CBD was the primary constituent of the industrial hemp extract,
trace THC was present in both LOW and HIGH treatments
(1.1 ± 0.37 and 2.9 ± 0.22mg THC/day, respectively). Treats
were formulated to target CBD at doses of 2.5 and 5.0 mg/kg
BW/day for LOW and HIGH treatments, respectively, based on
an estimation that dogs would weigh an average of 16 kg. The
LOW dose was selected based on previous literature that utilized
a similar dose in dogs to assess single-dose pharmacokinetics of
CBD and to evaluate its potential to alleviate pain in dogs with
osteoarthritis (35). That dose was then doubled to achieve the
HIGH dosage. However, based on the mean BW of the dogs
included in the study and analysis of the treats, the mean doses
of CBD were 1.8 and 4.5mg CBD/kg BW/day for the LOW and
HIGH treatments, respectively. Treats were offered solely as a
reward upon kennel reentry following twice-daily exercise, which
occurred within 30min of meals.
Experimental Design and Data Collection
Upon completion of intake exams, the dogs underwent a 7-
day acclimation period for adjustment to the environment, diet,
collars, and daily routine (Table 1). Kennels were maintained
on a 12-h light schedule. Dogs received two 15-min exercise
TABLE 1 | Schedule of events for monitoring activity in dogs receiving
cannabidiol-containing treats.
Day of study Event Data collection Treats
−2 and −1 Intake and initial health exams None Control
1 to 7 Acclimation None Control
8 to 21 Baseline period activity collection Vetrax activated Control
22 to 28 Treatment adaptation None Treatment
29 to 43 Treatment period activity collection Vetrax activated Treatment
periods each day, with the morning exercise occurring between
0700 and 0900 h and the evening exercise occurring between
1,700 and 1,900 h. During the exercise periods, dogs that were
aggressive toward other dogs were individually hand-walked by
research personnel; all other dogs were allowed to exercise freely
in playgroups of two to four dogs in one of two adjacent grassy
enclosures. The numbers of dogs being hand-walked and those
in playgroups were balanced across all treatments. Four hours
each day—from 1,000 to 1,200 h (a.m.) and from 1,330 to 1,530 h
(p.m.)—were designated as times when no people were allowed
to enter the kennels. Two of those 4 h were designated as Quiet
time and the other 2 h as Music time, when calming music was
played over speakers in each kennel. Quiet and Music sessions
were randomly allotted to either a.m. or p.m. time each day. All
dogs started receiving control treats (0mg CBD) twice daily as a
reward for kennel reentry after the twice-daily exercise.
After the acclimation period, Vetrax R© activity sensors
(AgLogica Holdings, Norcross, GA) were fitted to dogs’ collars
using the attachment provided by the manufacturer and placed
ventral to the mandible. These triaxial accelerometers were
used for the continuous collection of activity variables—activity
points, activity duration (in minutes), duration of no activity
(in hours), duration of resting (in hours), running duration (in
minutes), walking duration (in minutes), scratching duration (in
seconds), head shaking duration (in seconds), and sleep quality
(Table 2). Data collected by the sensors were automatically
uploaded to the Vetrax R© server via Wi-Fi once an hour
for behavior algorithm processing, which has been previously
validated (8). Except for a weekly consistent 2- to 3-h charging
period, sensors remained on the dogs at all times. Before the
start of the experiment, the data were collected over a 14-
day baseline period to block dogs by mean daily activity—high
(mean = 118.6min, range = 88.6–157.5min) or low (mean =
59.3min, range = 30.2–85.1min)—before stratifying dogs by
age, weight, and sex and randomly assigning dogs within each
block to treatments. Dogs were stratified by treatment and sex,
evenly distributed between the two kennels, and adapted to
treatments for 7 days before another 14-day collection of activity
via Vetrax R© sensors (Table 1).
Consumption of food and treats, consistency of stool,
frequency of elimination, subjective assessment of activity during
exercise, mucus membrane color, and other indicators of general
health status were monitored twice daily by research personnel.
Evidence of any adverse event—defined as any symptom
occurrence that would not be expected in normal dogs—was
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TABLE 2 | Activity variables measured by Vetrax® activity sensors (AgLogica
Holdings, Inc., Norcross, GA).
Variable Definition
Activity points Total activity of dogs weighted by each individual
activity (e.g., running worth more points than
walking), calculated using a proprietary algorithm
Activity (min) Duration of total activity including running and
walking
No activity (h) Duration of complete inactivity
Resting (h) Duration of time not actively walking or running, but
not completely inactive
Running (min) Duration of running
Walking (min) Duration of walking
Scratching (s) Time spent scratching
Head shaking (s) Time spent shaking head
Sleep Scale of sleep quality measured using a proprietary
algorithm based on absence of nighttime
disturbance; scaled 0 – 100, with 100 being
undisturbed sleep
also monitored. However, no adverse events were observed in
any dogs following the administration of CBD treats during
this study.
Statistical Analysis
Based on variations in activity and behaviors reported in previous
work using these sensors (8, 13), it was calculated that n = 8
dogs/treatment was sufficient to detect a 25% change with a 16%
coefficient of variation (CV) (45). Activity monitors for two of the
dogs in the control group (one in the high-activity block and one
in the low-activity block) spontaneously stopped transmitting
halfway through the treatment period, and activity data from the
last 7 days of the experiment for those two dogs were lost.
The normality of the residuals was tested using the
UNIVARIATE procedure in SAS (SAS Institute, Cary, NC). In
instances where the data did not meet normality assumptions,
statistical analysis was performed on transformed data. However,
the data were then back-transformed for reporting purposes. The
standard errors of the back-transformed data were calculated
from the confidence limits of the transformed data as follows:
SEM = (back-transformed upper limit – back-transformed
lower limit)/3.92. The denominator relates to the Z-value of
a 95% confidence interval (±1.96). For the baseline period,
activity duration, running, scratching, and head shaking were
not normally distributed and were log-transformed for statistical
analysis. Activity points and walking were not normally
distributed and were transformed into the square root for
statistical analysis.
During the baseline period, dogs allotted to CBD treatments
tended (P = 0.061) to run more than the control; thus, the
mean duration of running from the baseline period was utilized
as a covariate for the duration of running in the treatment
period. All other variables were similar across treatments in the
baseline period. For overall daily activity during the treatment
period, running, scratching, and head shaking were not normally
distributed and were log-transformed for statistical analysis. For
Quiet and Music session activity periods, all variables, except
for No Activity and Resting, were not normally distributed
and were log-transformed for statistical analysis. For exercise
activity periods, activity points, activity duration, and scratching
were not normally distributed and were log-transformed for
statistical analysis, whereas running and head shaking were not
normally distributed and were transformed to the cube root for
statistical analysis.
From the treatment period, overall daily activity and activity
during the exercise periods (0700–0900 and 1,700–1,900 h)
were analyzed using the MIXED procedure in SAS including
the fixed effects of treatment, day, and the treatment by day
interaction. Dog nested within the activity block (high or low)
was included as a random effect and day was included as
a repeated measure with dog nested within treatment as the
subject. Activity during the Quiet and Music sessions was
analyzed using the MIXED procedure in SAS including the fixed
effects of treatment, day, session (Quiet or Music), time of day
(a.m. or p.m.), and all accompanying interactions. Dog nested
within the activity block was again included as a random effect.
Time (a.m. or p.m.) was included as a repeated measure with
dog nested within treatment as the subject. Treatment effects are
described as the contrast between CON and both CBD treatments
and the contrast between LOW and HIGH CBD treatments.
The results are presented as the mean ± SE. Effects were
considered significant when P ≤ 0.05 and considered a tendency
when P < 0.10.
RESULTS
Total Daily Activity
CBD did not alter the total activity points, activity duration, no
activity, resting, running, walking, head shaking, or sleep quality
compared to CON (P > 0.05; Table 3). However, CBD tended
to reduce scratching compared with CON (P = 0.071), but was
not different between the LOW and HIGH treatments (P =
0.209). The level of CBD inclusion (LOW vs. HIGH) did not
affect any variables measured (P > 0.05). With the exceptions of
activity duration, running, walking, and scratching, all variables
were affected by day of treatment (P < 0.05), but there were no
treatment by day interactions (P > 0.05).
Quiet and Music Session Activity
Overall, dogs were more active in the p.m. sessions than in
the a.m., with all variables affected by the time of day (P
< 0.001; Table 4). Activity points, activity duration, running,
walking, and resting increased in the p.m. compared to the
a.m. (P < 0.001), while the duration of No Activity decreased
in the p.m. compared to a.m. (P < 0.001). During these
sessions, the Music session tended to reduce activity points
(P = 0.055) and running (P = 0.098) compared to the Quiet
session. The Music session reduced activity duration (P =
0.002), walking (P < 0.001), and resting (P = 0.045) while
increasing the duration of no activity (P= 0.014) compared to the
Quiet session.
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TABLE 3 | Effect of treatment (TRT), day, and TRT*day interaction on total daily activity variables collected via Vetrax® activity sensors (AgLogica Technology, Norcross,
GA).
Treatment SEb P-value









Activity points 56,834 57,079 56,634 4,952.5 0.985 0.950 0.017 0.857
Activity (min) 80.1 82.7 82.0 11.90 0.882 0.966 0.421 0.773
No activity (h) 13.6 13.9 14.3 0.58 0.496 0.652 0.002 0.394
Resting (h) 8.8 8.5 8.1 0.43 0.364 0.513 <0.001 0.389
Running (min) 5.8 5.6 6.9 0.36 0.612 0.172 0.172 0.447
Walking (min) 76.2 76.5 71.8 10.94 0.878 0.760 0.531 0.749
Scratching (s) 69.6 35.8 51.9 7.33 0.071 0.209 0.162 0.485
Head shaking (s) 32.4 27.3 42.4 5.49 0.878 0.229 0.006 0.194
Sleep quality 77.2 76.1 75.1 2.21 0.500 0.722 0.029 0.679
Treatment effects are shown as the contrast between control (CON) and both CBD treatments (CBD) and the contrast between CBD treatments (LOW vs. HIGH).
aRunning, scratching, and head shaking were not normally distributed and were transformed for statistical analysis. Data were back-transformed for reporting purposes.
bStandard error (SE) of the back-transformed data was calculated as follows: SE = (back-transformed upper limit – back-transformed lower limit)/3.92.
TABLE 4 | Effect of treatment (TRT), day, session (Quiet or Music), time of day (a.m. or p.m.), and all relevant interactions on activity variables collected via Vetrax® activity


















Session Session*time TRT*time TRT*session Day
Activity points 2,884 2,509 2,308 148.6 0.152 0.550 <0.001 0.055 0.014 0.287 0.465 <0.001
Activity (min) 1.23 0.87 0.85 0.144 0.204 0.937 <0.001 0.002 0.076 0.079 0.257 <0.001
No activity (h) 1.21 1.25 1.34 0.059 0.273 0.327 <0.001 0.014 <0.001 0.013 0.443 0.002
Resting (h) 0.71 0.70 0.62 0.050 0.384 0.234 <0.001 0.045 <0.001 0.006 0.203 0.002
Running (min) 0.04 0.03 0.04 0.006 0.602 0.544 <0.001 0.098 0.078 0.369 0.834 0.223
Walking (min) 1.29 0.87 0.82 0.148 0.138 0.857 <0.001 <0.001 0.084 0.060 0.217 <0.001
Scratching (s) 4.18 2.29 2.62 0.413 0.030 0.612 <0.001 0.930 0.274 0.326 0.886 0.730
Head shaking (s) 1.78 1.65 1.82 0.128 0.882 0.600 <0.001 0.926 0.305 0.319 0.212 0.375
Treatment effects are shown as the contrast between control (CON) and both CBD treatments (CBD) and the contrast between CBD treatments (LOW vs. HIGH).
aExcept for No Activity and Resting, variables were not normally distributed and were transformed for statistical analysis. Data were back-transformed for reporting purposes. There
was no effect of the treatment by day or the session by time by treatment interactions on any variable (P > 0.05) and thus are not shown.
bStandard error (SE) of the back-transformed data was calculated as follows: SE = (back-transformed upper limit – back-transformed lower limit)/3.92.
Session by time interactions were observed for activity
points, no activity, and resting (P < 0.05; Table 4), and a
trend for session by time interactions was observed for activity
duration, running, and walking (P = 0.076, 0.078, and 0.084,
respectively). The type of session (Quiet or Music) did not
alter activity points or duration of activity during the a.m.
session (P = 0.502 and 0.522, respectively). When the Quiet
session was allotted to the p.m., however, activity points (P
= 0.002), duration of activity (P < 0.001), resting (P <
0.001), running (P < 0.001), and walking (P < 0.001) were
increased compared to when the Music session was allotted to
the p.m.. The durations of No Activity were similar between
the Quiet and Music sessions when allotted to the a.m.
(P = 0.230), but the duration was increased in the Music
session compared to the Quiet session when allotted to the
p.m. (P < 0.001).
Activity points, running, and head shaking were unaffected by
treatment and all treatment interactions during the Quiet and
Music sessions (P > 0.05; Table 4). Scratching was reduced by
CBD during the Quiet and Music sessions compared to CON (P
= 0.030), but the level of CBD inclusion did not affect time spent
scratching (P = 0.612).
A treatment by time interaction was observed for No Activity
and Resting (P = 0.013 and 0.006, respectively; Table 4), and
a trend for a treatment by time interaction was observed for
activity and walking duration (P= 0.079 and 0.060, respectively).
Regardless of Quiet or Music session, activity durations were
similar across treatments in the a.m. (P > 0.05), but dogs
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receiving HIGH CBD tended (1.44 ± 0.172min, P = 0.091) to
be less active than CON (2.64 ± 0.324min) in the p.m. and
tended (1.37 ± 0.162min, P = 0.059) to walk less than CON
(2.60 ± 0.326min) in the p.m.. Similarly, the duration of No
Activity was unaffected by treatment in the a.m. (P > 0.05), but
in the p.m. tended to increase in the HIGH CBD treatment (1.13
± 0.060 h) compared to both CON (0.95 ± 0.063 h) and LOW
(0.97 ± 0.060 h) treatments (P = 0.054 and 0.068, respectively).
Conversely, resting duration increased in the LOW treatment
(0.96 ± 0.051 h) compared to the HIGH treatment (0.80 ±
0.051 h) in the p.m. (P = 0.038), but similar across all other time
points and treatments (P > 0.05). There were no treatment by
session nor treatment by session by time interactions (P > 0.05)
for any variables measured. All activity variables were affected by
day of treatment period (P < 0.05), but there were no treatment
by day interactions (P > 0.05).
Exercise Activity
Neither CBD treatment nor inclusion level affected any variables
measured during the exercise periods (P > 0.05; Table 5). Day
of treatment period tended (P = 0.066) to affect scratching and
affected head shaking (P = 0.003), but no other variables were
impacted by day of treatment (P> 0.05). Additionally, there were
no treatment by day interactions (P > 0.05).
DISCUSSION
Triaxial accelerometer sensors were used in this study to
determine the effect of daily CBD dosing on activity in healthy
adult dogs by measuring daily activity, pruritic behaviors, and
an assessment of rest and sleep quality. The objective of this
study was to evaluate the impact of CBD on the daily activity of
healthy adult dogs with the hypothesis that CBD would reduce
the overall daily activity compared to the control. However, the
results showed that oral CBD administration did not alter the
overall daily activity of healthy adult dogs. The lack of effect
on overall daily activity and sleep quality was unexpected based
on previous reports of the sedative and hypnogenic effects of
CBD in rodent, human, and canine models. In humans and
rats, CBD doses ranging from ∼2 to 40 mg/kg BW/day have
been reported to induce sedative effects, improve sleep quality,
and increase total sleep time (41, 46, 47). However, more recent
work has reported CBD to have no influence on the sleep cycle
in humans (48), and others argue that CBD by itself does not
produce sedative effects but rather modulates the sedative effect
of 19-tetrahydrocannabinol (THC), even if THC is only present
in minute amounts (42, 49, 50).
The potential for the sedative effect of CBD to be caused by the
presence of THC may be supported by an escalating dose study
in dogs where placebo, CBD-predominant, THC-predominant,
and CBD/THC combination oils were administered to dogs
to evaluate the occurrence and severity of adverse events
after administration (43). Doses for the CBD-predominant oil
started at 1.7mg CBD/kg BW/day and were incrementally
increased to a maximum of 64.7mg CBD/kg BW/day over 30
days. Lethargy was reported with the CBD-predominant oil
formulation. However, that oil was not THC-free; it was reported
to contain 0.7 mg/ml THC (43). The industrial hemp extract
included in the CBD treats used in this experiment contained a
similar THC content to the oil reported in Vaughn et al. (43), but
did not produce a similar effect. The reason for these conflicting
results remains unclear. These differences could be due to the
difference in animals utilized for the study—shelter vs. research-
bred dogs—or the different modes of delivery—eating a treat
vs. oral gavage of an oil. There have been reports of variations
in the pharmacokinetics of CBD depending on the mode of
delivery. In one experiment, CBD-infused oil demonstrated an
increased maximum plasma CBD concentration compared to
the same dose administered as microencapsulated oil beads and
a CBD-infused transdermal cream (51). Other reports using
similar doses of oral CBD oil and chews showed an increased
maximum plasma CBD concentration when administered as a
chew compared to an oil; however, this has yet to be investigated
in a single, controlled experiment (35, 52). Additionally, the dogs
used in Vaughn et al. (43) fasted before the administration of
CBD oil, whereas the dogs in the current experiment consumed
CBD treats within 30min of a meal. It has been suggested
that administering cannabinoids with a fat meal increased
bioavailability (53). Since the CBD used in Vaughn et al. (43) was
mixed in a lipid-based formulation, it is unclear whether these
differences in methodology would lead to the difference in the
sedative effects observed between their report and the current
study. Additional investigation using THC-free CBD is needed to
evaluate the potential for CBD to exert a sedative effect in dogs.
While there was no observed effect on the overall daily
activity with CBD treatment, it tended to influence activity
during different times of the day. The dogs in the current study
were more active in the p.m. than in the a.m. regardless of
treatment and type of session. Playing calming music in the
kennels (Music session) did reduce activity compared to when
no music was played (Quiet session), which supports previous
work showing that playing music can reduce stress and increase
relaxed behaviors in kenneled dogs (54–56). This effect, however,
appears to be independent of the effect of CBD as there was
no interaction between treatment and session nor a treatment
by session by time interaction. The tendency for dogs in the
HIGH CBD treatment to be less active than CON dogs in the
p.m. may indicate that CBD exerted some sedative or calming
effect on the dogs. However, this potential sedative effect was
expected to be observed in the a.m., as previous pharmacokinetic
reports have shown a half-life for CBD of 1–4 h (35, 51, 52, 57).
As this effect was not observed during the a.m. sessions, exercise
periods, or overall daily activity, these collective results do not
support a sedative or calming effect of CBD in dogs. Thus,
the claim that CBD exerts a sedative or calming effect in dogs
remains unsubstantiated, but further investigation may provide
clarification of these results.
In the present study, dogs were necessarily regimented into a
strict schedule of daily activities. It is possible that, in a setting
where dogs were entirely free to choose their activities, such
as a home, the outcome could have been different. The strict,
consistent schedule of the kennel environment did not allow
for much activity outside of the scheduled exercise periods,
which may have prevented normally high-energy dogs from
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TABLE 5 | Effect of treatment (TRT), day, and TRT*day interactions on activity parameters collected via Vetrax® activity sensors (AgLogica Technology, Norcross, GA)
during the two periods of daily exercise, which included all data from 0700–0900 to 1,700–1,900 h each day.
Treatment P-value
Variablea Control (CON) 1.8 mg/kg BW/day CBD (LOW) 4.5 mg/kg BW/day CBD (HIGH) SEb CON vs. CBD LOW vs. HIGH Day TRT*day
Activity points 21,736 25,735 26,122 2,096.8 0.143 0.910 0.117 0.283
Activity (min) 37.66 48.09 48.07 3.213 0.143 0.998 0.528 0.305
No activity (h) 0.82 0.75 0.77 0.132 0.708 0.899 0.359 0.842
Resting (h) 2.47 2.24 2.31 0.116 0.312 0.838 0.338 0.847
Running (min) 4.9 4.5 5.3 0.31 0.940 0.298 0.258 0.531
Walking (min) 35.0 43.8 40.7 0.12 0.207 0.446 0.958 0.576
Scratching (s) 21.1 14.1 20.3 2.53 0.442 0.267 0.066 0.875
Head shaking (s) 17.8 14.7 25.8 0.27 0.682 0.167 0.003 0.273
Treatment effects are shown as the contrast between control (CON) and both CBD treatments (CBD) and the contrast between CBD treatments (LOW vs. HIGH).
aExcept for No Activity and Resting, variables were not normally distributed and were transformed for statistical analysis. Data were back-transformed for reporting purposes.
bStandard error (SE) of the back-transformed data was calculated as follows: SE = (back-transformed upper limit – back-transformed lower limit)/3.92.
being as active as they could be with consistent free access to
more space. Conversely, shelter environments have been shown
to increase activity in dogs compared to a home environment
and may prevent dogs from resting due to increased stress
(58, 59). This may have artificially increased activity in dogs that
would have otherwise been less active. As a result, it may be
preferable to evaluate the effect of these treatments in familiar
environments that have more space for dogs to exhibit normal
activity and rest behaviors. Additionally, the small sample size
and the use of healthy adult dogs were limitations of this study.
The dogs included in this study exhibited high variability in
voluntary activity despite being blocked by baseline activity and
having no knownmobility or behavioral issues. These limitations
may preclude the extrapolation of these results to other canine
populations. Since CBD is often used to increase comfort and
activity in dogs with mobility issues like osteoarthritis or to
decrease the activity of anxious or hyperactive dogs (27), future
work should evaluate voluntary activity in animals with mobility
or behavioral issues like osteoarthritis or anxiety.
The results from this study suggest a potential antipruritic
effect of CBD. Phytocannabinoids like CBD act on the
body through the endocannabinoid system (ECS), which is a
signaling system including endocannabinoids like anandamide
and 2-arachidonylglycerol, their receptors, and regulatory
enzymes (60). The ECS helps regulate metabolic homeostasis,
thermoregulation, epidermal homeostasis, and more (61, 62).
While CBD has little to no affinity for CB1 and CB2 ECS
receptors, it is a known agonist for the transient receptor
potential vanilloid family of receptors (TRPV1-4), which are
known ECS receptors widely expressed in the skin and play a role
in itch sensation (61, 63–65). As TRPV1 is rapidly desensitized
after activation, it is thought that CBD may exert antipruritic
effects by keeping TRPV1 desensitized, thus preventing neuronal
activation by irritants (66–68). Additionally, CBD has been
shown to be an antagonist for transient receptor potential
melastatin 8 (TRPM8) receptors (67, 69). In the skin, TRPM8
is responsible for environmental cold detection and has been
suggested to contribute to the perception of pain and itch,
which may indicate that it is another target for the potential
antipruritic effect of CBD (64, 70). The antipruritic effect of
cannabinoids has been observed in humans (71–73), but this
is the first report of a potential antipruritic effect of CBD in
dogs as a reduction in scratching duration was observed in dogs.
While this experiment was not designed to assess the antipruritic
effect of CBD, these results may suggest a potential for CBD to
be beneficial in the treatment of skin conditions and pruritic
behaviors in dogs. To investigate this potential effect, it would
be beneficial for future work to specifically examine the effect of
CBD in dogs with skin issues such as allergies, atopic dermatitis,
or unexplained pruritus.
CONCLUSIONS
The results of the current study indicate that when supplemented
with up to 4.5 mg/kg BW/day, CBD does not impact the overall
daily activity of adult dogs. Total daily activity including duration
of the activity, sleep quality, and resting were unaffected by CBD.
Similarly, activity during the exercise periods was also unaffected
by CBD. During the Quiet and Music session periods, 4.5mg
CBD/kg BW/day tended to reduce activity in dogs compared to
both 1.8mg CBD/kg BW/day and CON, but this did not translate
to an overall daily effect. Playing classical music in the kennels
reduced activity compared to having nomusic played, but did not
alter the response to CBD. CBD reduced total daily scratching
as well as scratching during the Quiet and Music sessions,
which may indicate a possible antipruritic effect. Future work
examining the effect of CBD on activity is warranted, particularly
in dogs with mobility and behavioral issues like osteoarthritis
and anxiety. Additionally, the potential antipruritic effect of CBD
should be investigated using dogs with dermatological issues like
skin allergies or atopic dermatitis.
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